MBX Biosciences to Participate in Upcoming November Investor Conferences
CARMEL, Ind. and BURLINGTON, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Steve Hoerter, Chairman and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at, and participate in, the following upcoming investor conferences:
Covered in this story
Analyst targets on Mbx Biosciences Inc
- UBS: $57.5 → $90 by Sep 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MBX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Mbx Biosciences Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.